Immunotherapy for pancreatic cancer
Pancreatic cancer immunotherapy (or immuno-oncology) is a new area of treatment for pancreatic cancer. The mechanism of action is the stimulation of the human immune system to fight tumor cells.
Traditional pancreatic cancer treatments include surgical resection, radiotherapy, ablative treatments, and chemotherapy.
Currently, studies are also underway on several immunotherapy drugs to treat pancreatic carcinoma or pancreatic adenocarcinoma. Some drugs show impressive results.
Pembrolizumab (Keytruda®) is an immunosuppressive drug that activates the body’s immune system to fight cancer. The drug works by blocking the 1-PD protein found on immune system T cells, thus restoring T cells to the ability to identify and destroy the cancer cells. This treatment is only suitable for patients whose tumor is MMR-D or MSI-H.
The drug is given every three weeks, by intravenous infusion for 30 minutes. Possible side effects include exhaustion and fatigue, nausea and vomiting, bruising and bleeding, diarrhea, headache and joint pain.
Immunotherapy drugs are also used in Israel for a personalized treatment for each patient.
Personalized treatment can be prescribed by our doctor based on the results of new molecular genetic tests, during which the genomic profile of the tumor of the gastric adenorcarcinoma is compiled. These tests give a high prognosis of the likelihood of treatment with drugs that are suitable for a particular patient.